drugset / Trial / NCT03515044

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

NCT03515044

Phase 2 Completed 71 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE).

Timeline

Start
2018-09-13
Primary completion
2020-03-12
Completion
2020-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 40 mg
Subject Rifaximin Other / unclassified 80 mg